Saredutant

Saredutant is a selective NK2 receptor antagonist.

Signaling Pathways >> GPCR/G Protein >> Neurokinin Receptor

Signaling Pathways >> Neuronal Signaling >> Neurokinin Receptor

Research Areas >> Neurological Disease

NK2

Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Saredutant has dose-dependent effects on swim test immobility, with the low dose of 1 mg/kg having no effect and the doses of 3 and 10 mg/kg significantly reducing immobility[1].

Rats[1] In the first experiment the dose-related effects of Saredutant are investigated. The Flinders Sensitive Line (FSL) rats (n=8) are treated with one of the following: vehicle (carboxymethylcellulose-CMC) or 1, 3, or 10 mg/kg Saredutant, or 5 mg/kg Desipramine as a positive control. Saredutant is injected at 1 mL/kg. The Flinders Resistant Line (FRL) rats are given CMC or 3 mg/kg Saredutant. All injections are i.p. and are given for 14 consecutive days. Approximately 22 h after the last injections the rats are placed in the social interaction chamber with similarly treated rats for a 5-min recording. Then about 2 h later the rats are individually tested in the forced swim test for a single 5-min session[1].

[1]. Overstreet DH, et al. Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with Desipramine in an animal model of depression. Pharmacol Biochem Behav. 2010 Aug;96(2):206-10.

Substance P acetate salt | rolapitant | SB-222200 | Fezolinetant | Netupitant | [Sar9,Met(O2)11]-Substance P TFA | MLE-4901 | Succinyl-(Asp6,N-Me-Phe8)-Substance P (6-11) | Maropitant | NKP608 | Serlopitant | Talnetant | Y1 receptor antagonist 1 | [bAla8]-Neurokinin A(4-10)